Nick Cammack

Nick Cammack was most recently Head of Exploratory Discovery at GSK, and previously Head of the Medicines Development Campus for Diseases of the Developing World. In this role, Nick was responsible for the discovery and development of medicines to treat some of the most devastating neglected diseases including malaria, tuberculosis, Chagas disease and Leishmaniasis, and also including the recent registration and approval of Tafenoquine for vivax malaria.

Before joining GSK, Nick Cammack was Global Head of the Virology Disease Biology Area at Hoffmann La Roche, based in Palo Alto, California, USA, where he was instrumental in the initiation and implementation of many significant external partnerships - the three-way Roche-Pharmasset-InterMune partnership was the first to conduct and demonstrate antiviral activity of an interferon-free combination of two small molecules for the treatment of Hepatitis C.

Nick has also contributed to the discovery and development of three anti-HIV medicines and whilst at Roche in the UK where he was Head of the HIV Disease Area, he led the Roche-Trimeris Virology Team resulting in the successful launch of the novel anti-HIV medicine, Fuzeon.

Nick is a graduate of Leeds University and held a MRC PhD Fellowship at the London School of Hygiene and Tropical Medicine.

He is a member of the Organising and Scientific Committees for several international conferences.